Intercept 747-303 - A phase 3 double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of Obeticholic acid in subjects with Nonalcoholic Steatohepatitis.

Administered By

Awarded By

Contributors

Start/End

  • September 1, 2015 - August 31, 2022